CW
JAZZ icon

Connectus Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Connectus Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,388
Closed -$956K – 523
2023
Q3 		$956K Buy
7,388
+1,336
+22% +$178K 0.02% 316
2023
Q2 		$750K Sell
6,052
-15,807
-72% -$2.13M 0.02% 310
2023
Q1 		$3.2M Buy
21,859
+4,740
+28% +$701K 0.08% 180
2022
Q4 		$2.73M Buy
+17,119
New +$2.51M 0.06% 185
2022
Q1 		– Sell
-5,381
Closed -$686K – 388
2021
Q4 		$686K Buy
+5,381
New +$707K 0.03% 249

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Connectus Wealth's JAZZ Position: Q4 2023 in Review

Connectus Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 7,388 shares — an estimated $956K sold.

Connectus Wealth first reported a position in JAZZ in Q4 2021 and held it in 5 quarters. The position peaked at $3.2M in Q1 2023. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Connectus Wealth reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Connectus Wealth sold 7,388 Jazz Pharmaceuticals shares in Q4 2023, an estimated $956K.
  • Connectus Wealth first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Connectus Wealth's Jazz Pharmaceuticals position peaked at $3.2M in Q1 2023.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Connectus Wealth's 13F filing for Q4 2023, filed 14 Feb 2024.